Expedition 3 trial, paid for by Eli Lilly, hopes to gain approval before being released...read somewhere that the Alzheimer's drug and pharmaceutical industry will demand somewhere in the neighborhood of 5 billion a year...this explains why the big boys (Eli Lilly, Pfizer and Novartis) are shoring up this Solanezamub product for the market, perfecting the outcome effect wished...and gaining FDA approval in the process.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.